Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

CLIFFSIDE LABS L.L.C.

NPI: 1518366426 · MONMOUTH, NJ 08852 · Clinical Medical Laboratory · NPI assigned 08/15/2014

$325K
Total Medicaid Paid
6,369
Total Claims
5,466
Beneficiaries
37
Codes Billed
2018-01
First Month
2024-03
Last Month

Provider Details

Authorized OfficialDUNNE, LIAM (AUTHORIZED OFFICIAL)
NPI Enumeration Date08/15/2014

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 1,126 $101K
2019 304 $19K
2020 1,321 $101K
2021 957 $79K
2022 767 $8K
2023 1,500 $7K
2024 394 $10K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2,474 2,045 $99K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 699 550 $75K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 608 570 $49K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 491 405 $44K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 284 228 $31K
81307 44 41 $3K
82542 157 128 $3K
81404 69 58 $3K
81406 59 58 $2K
81405 56 55 $2K
81302 174 163 $2K
81321 45 41 $2K
81403 72 67 $1K
81238 79 73 $1K
81223 77 71 $1K
81249 51 50 $1K
81351 22 21 $1K
81317 31 28 $580.97
81311 77 71 $555.02
81320 25 25 $554.78
81334 30 27 $297.91
81256 77 70 $290.03
81298 31 28 $259.59
81479 Unlisted molecular pathology procedure 274 252 $256.66
81339 15 15 $167.44
81345 78 72 $167.44
81279 15 15 $167.44
81216 13 13 $167.39
81305 13 13 $158.58
81250 15 15 $52.88
81330 47 43 $47.00
81332 47 43 $43.65
81241 12 12 $0.00
81185 23 22 $0.00
81242 31 28 $0.00
81209 31 28 $0.00
81189 23 22 $0.00